XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue Recognition and Collaboration Arrangements        
Total net royalty revenue $ 89,508 $ 67,259 $ 266,905 $ 224,623
Royalty revenue        
Revenue Recognition and Collaboration Arrangements        
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)
Total net royalty revenue 57,056 53,558 179,213 172,681
GSK        
Revenue Recognition and Collaboration Arrangements        
Total net royalty revenue 57,056 53,558 179,213 172,681
GSK | Royalty revenue        
Revenue Recognition and Collaboration Arrangements        
Total royalties 60,512 57,014 189,581 183,049
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)
GSK | RELVAR/BREO        
Revenue Recognition and Collaboration Arrangements        
Total royalties 48,199 45,585 154,317 150,922
GSK | ANORO        
Revenue Recognition and Collaboration Arrangements        
Total royalties $ 12,313 $ 11,429 $ 35,264 $ 32,127